Gateway Investment Advisers LLC Gilead Sciences, Inc. Transaction History

Gateway Investment Advisers LLC

$9 Billion
Q3 2024

A detailed history of Gateway Investment Advisers LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Gateway Investment Advisers LLC holds 76,827 shares of GILD stock, worth $7.22 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

76,827

Previous 77,089 0.34%

Holding current value

$7.22 Million

Previous $5.29 Million 21.74%

% of portfolio

0.07%

Previous 0.06%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	SELL	$66.59 - $83.99 $17,446 - $22,005	-262 Reduced 0.34%	76,827 $6.44 Million
Q2 2024 Jul 12, 2024	SELL	$63.15 - $72.88 $8,525 - $9,838	-135 Reduced 0.17%	77,089 $5.29 Million
Q1 2024 Apr 12, 2024	SELL	$71.58 - $87.29 $8,589 - $10,474	-120 Reduced 0.16%	77,224 $5.66 Million
Q4 2023 Jan 09, 2024	SELL	$73.27 - $83.09 $10,037 - $11,383	-137 Reduced 0.18%	77,344 $6.27 Million
Q3 2023 Oct 19, 2023	SELL	$73.94 - $80.67 $65,510 - $71,473	-886 Reduced 1.13%	77,481 $5.81 Million
Q2 2023 Jul 13, 2023	SELL	$76.01 - $86.7 $101,473 - $115,744	-1,335 Reduced 1.67%	78,367 $6.04 Million
Q1 2023 Apr 11, 2023	BUY	$77.31 - $88.08 $12,678 - $14,445	164 Added 0.21%	79,702 $6.61 Million
Q4 2022 Jan 13, 2023	BUY	$62.32 - $89.47 $382,208 - $548,719	6,133 Added 8.36%	79,538 $0
Q3 2022 Oct 07, 2022	SELL	$59.54 - $68.01 $375,518 - $428,939	-6,307 Reduced 7.91%	73,405 $4.53 Million
Q2 2022 Jul 13, 2022	BUY	$57.72 - $65.01 $57,835 - $65,140	1,002 Added 1.27%	79,712 $4.93 Million
Q1 2022 Apr 14, 2022	SELL	$57.92 - $72.58 $60,294 - $75,555	-1,041 Reduced 1.31%	78,710 $4.68 Million
Q4 2021 Jan 14, 2022	SELL	$64.88 - $73.64 $92,843 - $105,378	-1,431 Reduced 1.76%	79,751 $5.79 Million
Q3 2021 Oct 22, 2021	SELL	$67.69 - $73.03 $261,148 - $281,749	-3,858 Reduced 4.54%	81,182 $5.67 Million
Q2 2021 Jul 13, 2021	SELL	$63.47 - $69.35 $46,650 - $50,972	-735 Reduced 0.86%	85,040 $5.86 Million
Q1 2021 Apr 14, 2021	SELL	$60.0 - $68.46 $57,540 - $65,653	-959 Reduced 1.11%	85,775 $5.54 Million
Q4 2020 Jan 14, 2021	BUY	$56.65 - $64.55 $63,504 - $72,360	1,121 Added 1.31%	86,734 $5.05 Million
Q3 2020 Oct 19, 2020	SELL	$62.1 - $78.08 $421,100 - $529,460	-6,781 Reduced 7.34%	85,613 $5.41 Million
Q2 2020 Jul 15, 2020	SELL	$72.34 - $84.0 $762,752 - $885,696	-10,544 Reduced 10.24%	92,394 $7.11 Million
Q1 2020 Apr 13, 2020	SELL	$62.63 - $80.22 $29.9 Million - $38.3 Million	-476,846 Reduced 82.25%	102,938 $7.7 Million
Q4 2019 Jan 09, 2020	SELL	$61.62 - $67.78 $7.53 Million - $8.29 Million	-122,278 Reduced 17.42%	579,784 $37.7 Million
Q3 2019 Oct 15, 2019	SELL	$62.51 - $69.0 $2.4 Million - $2.65 Million	-38,465 Reduced 5.19%	702,062 $44.5 Million
Q2 2019 Jul 17, 2019	SELL	$61.87 - $69.38 $585,413 - $656,473	-9,462 Reduced 1.26%	740,527 $50 Million
Q1 2019 Apr 10, 2019	BUY	$62.53 - $70.05 $1.46 Million - $1.63 Million	23,310 Added 3.21%	749,989 $48.8 Million
Q4 2018 Jan 14, 2019	SELL	$60.54 - $79.0 $16,103 - $21,014	-266 Reduced 0.04%	726,679 $45.5 Million
Q3 2018 Oct 16, 2018	SELL	$71.28 - $78.92 $194,451 - $215,293	-2,728 Reduced 0.37%	726,945 $56.1 Million
Q2 2018 Jul 11, 2018	SELL	$64.88 - $75.68 $366,701 - $427,743	-5,652 Reduced 0.77%	729,673 $51.7 Million
Q1 2018 Apr 12, 2018	SELL	$72.84 - $88.8 $3.17 Million - $3.86 Million	-43,465 Reduced 5.58%	735,325 $55.4 Million
Q4 2017 Jan 17, 2018	SELL	$71.15 - $83.52 $3.26 Million - $3.82 Million	-45,771 Reduced 5.55%	778,790 $55.8 Million
Q3 2017 Oct 16, 2017	BUY	$72.11 - $85.47 $59.5 Million - $70.5 Million	824,561	824,561 $66.8 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gateway Investment Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gateway Investment Advisers LLC with notifications on news.

Account

Gateway Investment Advisers LLC Gilead Sciences, Inc. Transaction History